Nucleus Genomics charges $9,999 for an analysis of up to 20 embryos: diseases, eye color, baldness, intelligence. According to the Financial Times, the service is available in more than 165 clinics. The investor is Peter Thiel's Founders Fund. The promise of "the best child" has become a paid genetic rating. The selection allows you to choose from existing embryos. Editing will change their DNA. Nucleus is funding editorial research at Columbia University and intends to offer it to customers. Entrepreneur Kian Sedgoye, founder of Nucleus, is preparing buyers for the future service even before it is scientifically approved. Preventive raised about $30 million in 2025, with investors including OpenAI CEO Sam Altman and Coinbase CEO Brian Armstrong. The company's founder, the biotech Lucas Harrington, promises to first test the safety of treating severe hereditary diseases. Bootstrap Bio shut down without new investments Disbanded after a conflict between the founders. Entrepreneur Katie Tay, who participated in the creation of Manhattan, launched Origin Genomics in March 2026. The previous companies did not make a scientific breakthrough. Investors are still interested in customers. University science still brings uncomfortable news. In September 2026, Columbia University researcher Dieter Eglie and his colleagues reported in Nature the successful modification of the PCSK9 gene in human embryos. Along the way, chromosome damage and mosaicism occurred: the fetal cells underwent various DNA edits. When the editor was introduced in RNA form, development often stopped. The authors ruled out the reproductive use of current technology. Co-author Natan Teraf serves as Nucleus' medical director. The article does not mention her among those who financed the research. Exact replacement of a DNA signal does not guarantee health. One gene can affect several functions of the body, and a hereditary error can be passed on to offspring.

Nucleus Genomics charges $9,999 for an analysis of up to 20 embryos: diseases, eye color, baldness, intelligence. According to the Financial Times, the service is available in more than 165 clinics. The investor is Peter Thiel's Founders Fund. The promise of "the best child" has become a paid genetic rating. The selection allows you to choose from existing embryos. Editing will change their DNA. Nucleus is funding editorial research at Columbia University and intends to offer it to customers. Entrepreneur Kian Sedgoye, founder of Nucleus, is preparing buyers for the future service even before it is scientifically approved. Preventive raised about $30 million in 2025, with investors including OpenAI CEO Sam Altman and Coinbase CEO Brian Armstrong. The company's founder, the biotech Lucas Harrington, promises to first test the safety of treating severe hereditary diseases. Bootstrap Bio shut down without new investments Disbanded after a conflict between the founders. Entrepreneur Katie Tay, who participated in the creation of Manhattan, launched Origin Genomics in March 2026. The previous companies did not make a scientific breakthrough. Investors are still interested in customers. University science still brings uncomfortable news. In September 2026, Columbia University researcher Dieter Eglie and his colleagues reported in Nature the successful modification of the PCSK9 gene in human embryos. Along the way, chromosome damage and mosaicism occurred: the fetal cells underwent various DNA edits. When the editor was introduced in RNA form, development often stopped. The authors ruled out the reproductive use of current technology. Co-author Natan Teraf serves as Nucleus' medical director. The article does not mention her among those who financed the research. Exact replacement of a DNA signal does not guarantee health. One gene can affect several functions of the body, and a hereditary error can be passed on to offspring.